361 related articles for article (PubMed ID: 25395071)
1. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Sakellariou G; Savvidis M; Papatheodorou A; Kokkoris P; Terpos E
Expert Opin Ther Targets; 2015 Mar; 19(3):299-306. PubMed ID: 25395071
[TBL] [Abstract][Full Text] [Related]
2. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
3. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.
Terpos E; Ntanasis-Stathopoulos I; Christoulas D; Bagratuni T; Bakogeorgos M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Dimopoulos MA
Blood Cancer J; 2018 May; 8(5):42. PubMed ID: 29748532
[TBL] [Abstract][Full Text] [Related]
5. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-Derived Semaphorin 4D Induces Inflammatory Cytokine Production of Endothelial Cells via Different Plexin Receptors in Kawasaki Disease.
Huang J; Wu S; Cao S; Zhu X; Zhang S
Biomed Res Int; 2020; 2020():6663291. PubMed ID: 33381571
[TBL] [Abstract][Full Text] [Related]
7. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Rauner M; Sonnleitner L; Hawa G; Tsourdi E; Yavropoulou MP; Missbichler A; Terpos E
J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):253-257. PubMed ID: 31475931
[TBL] [Abstract][Full Text] [Related]
8. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
9. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
11. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
12. Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.
Anastasilakis AD; Polyzos SA; Makras P; Savvides M; Sakellariou GT; Gkiomisi A; Papatheodorou A; Terpos E
Horm Metab Res; 2014 Feb; 46(2):145-9. PubMed ID: 23918682
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
14. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
15. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
Anastasilakis AD; Makras P; Pikilidou M; Tournis S; Makris K; Bisbinas I; Tsave O; Yovos JG; Yavropoulou MP
J Clin Endocrinol Metab; 2018 Mar; 103(3):1206-1213. PubMed ID: 29309589
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Semaphorin 4D/Plexin-B1 signaling inhibits the subchondral bone loss in early-stage osteoarthritis of the temporomandibular joint.
Zhang Z; Lu L; Ye T; Yu S; Zhang J; Zhang M; He F; Liu Q; Yang H; Feng J
Arch Oral Biol; 2022 Mar; 135():105365. PubMed ID: 35151027
[TBL] [Abstract][Full Text] [Related]
17. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
18. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Savvides M; Papatheodorou A; Terpos E
Osteoporos Int; 2013 Jul; 24(7):2127-32. PubMed ID: 23124716
[TBL] [Abstract][Full Text] [Related]
19. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
20. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
Cao J; Zhang C; Chen T; Tian R; Sun S; Yu X; Xiao C; Wang G; Liu Y; Fu M; Li W
J Dermatol Sci; 2015 Aug; 79(2):127-36. PubMed ID: 26051877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
